| Product Code: ETC10756539 | Publication Date: Apr 2025 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Angola PD-1 Non-Small Cell Lung Cancer Market Overview |
3.1 Angola Country Macro Economic Indicators |
3.2 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, 2021 & 2031F |
3.3 Angola PD-1 Non-Small Cell Lung Cancer Market - Industry Life Cycle |
3.4 Angola PD-1 Non-Small Cell Lung Cancer Market - Porter's Five Forces |
3.5 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.6 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Therapy Type, 2021 & 2031F |
3.7 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Treatment Stage, 2021 & 2031F |
3.8 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By Mode of Action, 2021 & 2031F |
3.9 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Angola PD-1 Non-Small Cell Lung Cancer Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidences of non-small cell lung cancer in Angola |
4.2.2 Growing awareness and adoption of PD-1 inhibitors for cancer treatment |
4.2.3 Advancements in medical research leading to the development of more effective PD-1 inhibitors |
4.3 Market Restraints |
4.3.1 High cost associated with PD-1 inhibitor treatments |
4.3.2 Limited access to advanced healthcare facilities in certain regions of Angola |
5 Angola PD-1 Non-Small Cell Lung Cancer Market Trends |
6 Angola PD-1 Non-Small Cell Lung Cancer Market, By Types |
6.1 Angola PD-1 Non-Small Cell Lung Cancer Market, By Drug Type |
6.1.1 Overview and Analysis |
6.1.2 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Drug Type, 2021 - 2031F |
6.1.3 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-1 Inhibitors, 2021 - 2031F |
6.1.4 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By PD-L1 Inhibitors, 2021 - 2031F |
6.1.5 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Combination Therapy, 2021 - 2031F |
6.1.6 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Monotherapy, 2021 - 2031F |
6.1.7 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Adjuvant Therapy, 2021 - 2031F |
6.2 Angola PD-1 Non-Small Cell Lung Cancer Market, By Therapy Type |
6.2.1 Overview and Analysis |
6.2.2 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.2.3 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Chemotherapy, 2021 - 2031F |
6.2.4 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.2.5 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Surgery, 2021 - 2031F |
6.2.6 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Palliative Care, 2021 - 2031F |
6.3 Angola PD-1 Non-Small Cell Lung Cancer Market, By Treatment Stage |
6.3.1 Overview and Analysis |
6.3.2 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By First-Line Treatment, 2021 - 2031F |
6.3.3 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Second-Line Treatment, 2021 - 2031F |
6.3.4 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Advanced-Stage Treatment, 2021 - 2031F |
6.3.5 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Recurrent Cancer Treatment, 2021 - 2031F |
6.3.6 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Metastatic Cancer Treatment, 2021 - 2031F |
6.4 Angola PD-1 Non-Small Cell Lung Cancer Market, By Mode of Action |
6.4.1 Overview and Analysis |
6.4.2 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Targeted Therapy, 2021 - 2031F |
6.4.3 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Checkpoint Inhibitors, 2021 - 2031F |
6.4.4 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Biomarker-Based Therapy, 2021 - 2031F |
6.4.5 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Immune Checkpoint Modulation, 2021 - 2031F |
6.4.6 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By T-Cell Activation, 2021 - 2031F |
6.5 Angola PD-1 Non-Small Cell Lung Cancer Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.5.3 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Research Labs, 2021 - 2031F |
6.5.4 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Oncology Centers, 2021 - 2031F |
6.5.5 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Clinics, 2021 - 2031F |
6.5.6 Angola PD-1 Non-Small Cell Lung Cancer Market Revenues & Volume, By Diagnostic Centers, 2021 - 2031F |
7 Angola PD-1 Non-Small Cell Lung Cancer Market Import-Export Trade Statistics |
7.1 Angola PD-1 Non-Small Cell Lung Cancer Market Export to Major Countries |
7.2 Angola PD-1 Non-Small Cell Lung Cancer Market Imports from Major Countries |
8 Angola PD-1 Non-Small Cell Lung Cancer Market Key Performance Indicators |
8.1 Number of clinical trials evaluating PD-1 inhibitors in Angola |
8.2 Rate of adoption of PD-1 inhibitors in non-small cell lung cancer treatment |
8.3 Percentage of oncologists recommending PD-1 inhibitors as part of the treatment protocol |
9 Angola PD-1 Non-Small Cell Lung Cancer Market - Opportunity Assessment |
9.1 Angola PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.2 Angola PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Therapy Type, 2021 & 2031F |
9.3 Angola PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Treatment Stage, 2021 & 2031F |
9.4 Angola PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By Mode of Action, 2021 & 2031F |
9.5 Angola PD-1 Non-Small Cell Lung Cancer Market Opportunity Assessment, By End User, 2021 & 2031F |
10 Angola PD-1 Non-Small Cell Lung Cancer Market - Competitive Landscape |
10.1 Angola PD-1 Non-Small Cell Lung Cancer Market Revenue Share, By Companies, 2024 |
10.2 Angola PD-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here